Baxdrostat showed promising results in Phase III trial for treatment-resistant hypertension, with FDA decision expected in 2026.

Recent high-profile recalls of glucose monitors and insulin pumps underscore vulnerabilities in devices millions depend on daily.

Baxdrostat reduced systolic pressure by up to 9.8 mmHg in 800-patient global trial published in NEJM.

Baxdrostat reduced stubborn hypertension by up to 9.8 mmHg in 796-patient global trial, though questions remain about long-term effects.

Electronic Frontier Foundation challenges CMS after only 62% of prior authorization requests initially approved.

Agency drops universal flu, COVID-19 shot advice amid severe flu season surge.

Teva's Ponlimsi becomes tenth biosimilar to denosumab, expanding affordable treatment options for bone disease.

New CDC study documents 3,434 kratom exposure reports in 2025, up from 258 in 2015, alongside 233 deaths.

CDC data shows record 3,434 calls in 2025, up from 258 in 2015, amid push for federal regulation.